| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | SVP, General Counsel | Common Stock | 39,755 | $649,994 | $16.35 | 18 Feb 2026 | Direct |
| Keros Therapeutics, Inc. | SVP, General Counsel | Employee Stock Option (Right to Buy) | 80,000 | 24 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 18 Feb 2026 | 1 | -$77,581 | 4 | SVP, General Counsel | 20 Feb 2026, 16:15 |
| KROS | Keros Therapeutics, Inc. | 05 Jan 2026 | 1 | $0 | 4 | Chief Legal Officer | 26 Feb 2026, 16:15 |
| KROS | Keros Therapeutics, Inc. | 06 Aug 2025 | 0 | $0 | 3 | SVP, General Counsel | 15 Aug 2025, 16:32 |